42.50 -0.06 (-0.14%)
Pre-Market: 8:00AM EST
|Bid||41.50 x 1200|
|Ask||42.58 x 800|
|Day's Range||42.36 - 43.85|
|52 Week Range||29.52 - 50.05|
|Beta (3Y Monthly)||2.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.50|
Yahoo Finance's Julie Hyman highlights today's stocks on the move in midday trading.
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
In 2016 Amit Munshi was appointed CEO of Arena Pharmaceuticals Inc (NASDAQ:ARNA). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, ...
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.
Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.
SAN DIEGO, Nov. 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the appointments of Robert Lisicki as Executive Vice President and Chief Commercial Officer, and Paul K. Audhya, MD, MBA, as Senior Vice President, Medical Affairs. Mr. Lisicki will report to Amit D. Munshi, Arena's President and Chief Executive Officer, and Dr. Audhya will report to Preston Klassen, MD, M.H.S., Executive Vice President, Research and Development and Chief Medical Officer.
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
SAN DIEGO, Calif. , Nov. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences: ...
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / Pharmaceutical companies Arena Pharmaceuticals and Sonoma Pharmaceuticals were in the green on Thursday. While Sonoma did not have any news to note, Arena Pharmaceuticals announced that it has entered into a lucrative licensing agreement with United Therapeutics. Arena Pharmaceuticals, Inc. shares were up 22.62% yesterday on around 4.7 million shares traded.
The deal between Arena Pharmaceuticals (NASDAQ:ARNA) and United Therapeutics has to do with the former’s ralinepag. The deal that has Arena Pharmaceuticals stock skyrocketing today is for the exclusive worldwide develop, manufacture and commercialize rights for ralinepag. This has United Therapeutics making an upfront payment of $800 million for those rights.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
Investors are the least optimistic on tech stocks like these since the depths of the financial crisis and are instead directing attention to another corner of the market: healthcare. REDUCE-IT suggests that the residual 65-75% cardiovascular risk beyond cholesterol management can be significantly lowered with Vascepa in studied patients.
United Therapeutics Corp on Thursday signed a deal potentially worth up to $1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc's pulmonary arterial hypertension treatment, ralinepag. The two companies said in a statement the deal for Arena's late-stage experimental treatment also includes milestone payments of up to $400 million based on certain regulatory events. Arena will receive low double-digit tiered royalties on annual net sales of ralinepag, the companies said.
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) and United Therapeutics Corporation (UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.
SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at the American Heart Association Scientific Sessions 2018.